Cullinan Therapeutics (CGEM) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics is the larger company by market cap ($960.6 million vs $945.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | SPTX |
|---|---|---|
| Share price | $15.63 | $17.67 |
| Market cap | $960.59M | $945.88M |
| 1-day change | -3.82% | -1.45% |
| YTD return | +51.01% | — |
| 1-year return | +165.37% | — |
| 5-year return | -37.48% | — |
| EPS (TTM) | $-3.11 | $-5.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $28.38 |
| 52-week low | $6.50 | $14.85 |
| Distance from 52-week high | -32.60% | -37.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +114.01% | +116.69% |
| Average volume | 871.08K | 182.18K |
| Shares outstanding | 61.46M | 53.53M |
| Employees | 109 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CGEM vs SPTX FAQ
Which is bigger, Cullinan Therapeutics or Seaport Therapeutics?
Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $960.59M compared with $945.88M for Seaport Therapeutics (SPTX).
Are Cullinan Therapeutics and Seaport Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cullinan Therapeutics and Biotechnology: Pharmaceutical Preparations for Seaport Therapeutics.